In this week’s podcast, Medtech Insight's Reed Miller highlights trial results from Boston Scientific and Medtronic at HRS 2020, and Marion Webb discusses the impact of COVID-19 on Q1 2020 earnings results of major orthopedics companies.
Listen to the podcast via the player below:
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.
A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.
Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.
